PCSK9 inhibitors: Alirocumab monotherapy reduced LDL cholesterol three times more than Ezetimibe
Sanofi and Regeneron Pharmaceuticals have announced that the Phase 3 ODYSSEY MONO trial with Alirocumab, an investigational monoclonal antibody targeting PCSK9 ( proprotein convertase subtilisin/kexin type 9 ), met its primary efficacy endpoint.
The mean low density lipoprotein-cholesterol ( LDL-C ) reduction from baseline to week 24, the primary efficacy endpoint of the study, was significantly greater in patients randomized to Alirocumab, as compared to patients randomized to Ezetimibe ( Ezetrol, Zetria ) ( 47.2% vs. 15.6%, p less than 0.0001 ).
In the trial, which employed a dose increase ( up-titration ) for patients who did not achieve an LDL-C level of 70 milligrams/deciliter ( mg/dL ), the majority of patients remained on the initial low dose of Alirocumab of 75 mg.
The percentage of patients who reported treatment emergent adverse events was 78.4% in the Ezetimibe group and 69.2% in the Alirocumab group.
The most common class of adverse events was infections ( 39.2% with Ezetimibe vs. 42.3% with Alirocumab ), which included nasopharyngitis, influenza, and upper respiratory tract infection.
Injection-site reactions occurred in less than 2% of patients in both groups.
Muscle-related adverse events occurred in 3.9% of patients treated with Ezetimibe and 3.8% of patients treated with Alirocumab.
ODYSSEY MONO is the first study to report data from the 12 Phase 3 trials that have been initiated so far as part of the more than 23,000 patient ODYSSEY clinical trial program.
ODYSSEY MONO ( n=103 ) was a randomized, double-blind, active-controlled, parallel-group study to evaluate the efficacy and safety of Alirocumab over 24 weeks in patients with primary hypercholesterolemia and moderate cardiovascular risk.
Patients in the trial were randomized to receive monotherapy with either Ezetimibe 10 mg, or Alirocumab.
Alirocumab was self-administered initially at its low dose of 75 mg every two weeks, and was up-titrated at week 12 to 150 mg if the LDL-C measurement at week 8 was above 70 mg/dL. The majority of Alirocumab patients in the trial remained on the initial low dose of Alirocumab because they achieved LDL-C below 70 mg/dL at week 8.
Alirocumab was self-administered subcutaneously using a single-use 1 mL auto-injector.
PCSK9 is known to be a determinant of circulating LDL levels, as it binds to LDL receptors resulting in their degradation so that fewer are available on liver cells to remove excess LDL-cholesterol from the blood.
Moreover, traditional LDL-lowering therapies such as statins actually stimulate the production of PCSK9, which limits their own ability to lower LDL-cholesterol.
Blocking the PCSK9 pathway is therefore a potentially novel mechanism for lowering LDL-cholesterol.
Alirocumab is an investigational, fully-human monoclonal antibody that targets and blocks PCSK9. It is administered via subcutaneous injection. By inhibiting PCSK9 Alirocumab has been shown in pre-clinical studies to increase the number of LDL receptors on hepatocytes, thereby lowering LDL cholesterol. ( Xagena )
Source: Sanofi, 2013
The ODYSSEY OUTCOMES ( Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab ) trial compared...
European Union has approved Praluent to reduce the risk of cardiovascular events in patients with established cardiovascular disease
The European Commission ( EC ) has approved a new indication for Praluent ( Alirocumab ), to reduce cardiovascular (...
Praluent to prevent myocardial infarction, stroke and unstable angina requiring hospitalization, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...
Heterozygous familial hypercholesterolemia: individualized low-density lipoprotein cholesterol reduction with Alirocumab titration strategy
Patients with heterozygous familial hypercholesterolemia ( HeFH ) who completed the double-blind ODYSSEY LONG TERM parent trial and subsequently enrolled...
ODYSSEY Alirocumab trials: lower major adverse cardiovascular events risk with lower LDL cholesterol levels
In statin trials, men and women have shown similar relative risk reductions in cardiovascular events per 39 mg/dL low-density lipoprotein...
Long-term safety and efficacy of Alirocumab in patients with heterozygous familial hypercholesterolemia
ODYSSEY OLE ( open-label extension ) has included patients diagnosed with heterozygous familial hypercholesterolemia ( HeFH ), receiving maximally tolerated...
Heterozygous familial hypercholesterolemia: 63% of patients treated with Alirocumab no longer required apheresis
Positive results from the phase 3 ODYSSEY ESCAPE trial evaluating Alirocumab ( Praluent ) injection in patients with an inherited...
A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin...
Anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia: systematic review of published phase 3 data
Two anti-proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) monoclonal antibodies, Alirocumab and Evolocumab, have been approved for the treatment...
ODYSSEY LONG TERM trial: robust and consistent LDL cholesterol lowering demonstrated with Alirocumab, a PCSK9 inhibitor
The 18-month ( 78-week ) results of a phase 3 trial of Alirocumab ( Praluent ), an investigational therapy, involving...